Shortages drive 4,500% price markup; Disgruntled IT worker hacks pharma company, deletes hosts;

> Amid growing drug shortages, some back-door suppliers are jacking up prices for meds to treat a number of conditions, including cancer and high blood pressure, by as much as 4,500%. Article

> Six Sigma is most appropriate for supplies or processes over which a company has tight control, and it might not be suitable for every aspect of pharmaceutical manufacturing. Story

> A former IT administrator at Japanese pharmaceutical company Shionogi has pleaded guilty to hacking the company network and deleting 15 VMware hosts. News

> Ranbaxy Laboratories is shutting down its quality-challenged manufacturing plant in Gloversville, NY. Item

> The thousands of job losses anticipated when Pfizer ($PFE) pulls up stakes in Sandwich, U.K., will initiate a recovery that could take 10 years, say officials. Report

> Hiring is increasing in Russia at multinational pharma companies, and the sector is among the three most active in terms of recruiting employees. Story

> Ampac Fine Chemicals ($APFC) will begin manufacturing the API for its smallpox drug at its recently completed facility in Rancho Cordova, ending its contract manufacturing agreement with Chimerix. Item

> Intellipharmaceutics ($IPCI) and Par Pharmaceutical ($PRX) have added the development and commercialization of additional strengths of generic Focalin XR to their agreement. Release

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.